Sarepta Therapeutics (SRPT) drew fresh attention after raising the low end of its 2026 net product revenue guidance to US$1.25b, alongside mixed third quarter numbers and updates across its gene therapy and siRNA programs.
At a share price of US$17.82, Sarepta Therapeutics has edged up with a 1.42% 1-day share price return and a 6.2% 90-day share price return, while the year-to-date share price return is down 16.38% and the 3-year total shareholder return has fallen 77.57%. This points to near-term momentum improving against a much weaker longer-run record.
Scan biotech ideas that echo Sarepta Therapeutics' mix of guidance shifts, earnings surprises, and pipeline catalysts by screening for 19 high quality undiscovered gems in the rare disease and therapeutics space.
Bulls point to Sarepta Therapeutics lifting guidance and a recovering earnings profile. Bears focus on revenue slipping year on year and a bruised long term share record. Which side does the valuation actually lean toward?
Most Popular Narrative: 18% Undervalued
Against the last close of $17.82, the most followed narrative on Sarepta Therapeutics points to a fair value of $21.73, framing the current price as meaningfully below that estimate and putting the spotlight firmly on its Duchenne cash engine and pipeline spend.
Sarepta Therapeutics is using a cash flow positive Duchenne muscular dystrophy portfolio, with Q2 2026 product gross margins of 75% and non GAAP operating income of US$86 million, to self fund pipeline work and potentially support future earnings and cash generation without relying on new equity.
See why 43 investors see Sarepta Therapeutics as 18% undervalued.
Result: Fair Value of $21.73 (UNDERVALUED)
Still, the Sarepta Therapeutics story can change quickly if ELEVIDYS safety concerns re-emerge or a rival exon 51 therapy takes meaningful Duchenne share.
Find out about the key risks to this Sarepta Therapeutics narrative.
Next Steps
Mixed signals on Sarepta Therapeutics can easily pull you toward either camp, so check the data directly, weigh both sides, and see the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Sarepta Therapeutics?
Do not stop at Sarepta Therapeutics. The same tools that surface its story can help you spot fresh opportunities other investors might miss entirely.
- Target resilient performers by filtering for companies with healthier balance sheets and fundamentals through the list of solid balance sheet and fundamentals (24 results).
- Zero in on quality at a discount by scanning companies flagged as potential value opportunities using the 39 high quality undervalued stocks.
- Strengthen your watchlist with fresh prospects by reviewing the 9 elite penny stocks with strong financials that involve higher risk and potentially higher reward.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com